Evidence map›Paper›PMID 29255034›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2018

Artificial antibody created by conformational reconstruction of the complementary-determining region on gold nanoparticles.

Gui-Hua Yan, Kun Wang, Zhuxue Shao, Lei Luo, Zheng-Mei Song, Jingqi Chen, Rong Jin, Xiaoyong Deng, Haifang Wang, Zhonglian Cao and 2 more

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Phage-Templated Synthesis of Targeted Photoactive 1D-Thiophene Nanoparticles.Small (Weinheim an der Bergstrasse, Germany) · 2025
    Article
  3. Review
  4. Making nanoparticles protein-like.Nanomedicine (London, England) · 2024
    Article
  5. Article
  6. Article
  7. Article
  8. [Progresses on active targeting liposome drug delivery systems for tumor therapy].Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi · 2022
    Review
  9. Article
  10. Review
  11. Article
  12. How the avidity of polymerase binding to the -35/-10 promoter sites affects gene expression.Proceedings of the National Academy of Sciences of the United States of America · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Gui-Hua YanInstitute of Nanochemistry and Nanobiology, Shanghai University, Shanghai 200444, China.
Kun WangInstitute of Nanochemistry and Nanobiology, Shanghai University, Shanghai 200444, China.
Zhuxue ShaoInstitute of Nanochemistry and Nanobiology, Shanghai University, Shanghai 200444, China.
Lei LuoInstitute of Nanochemistry and Nanobiology, Shanghai University, Shanghai 200444, China.
Zheng-Mei SongInstitute of Nanochemistry and Nanobiology, Shanghai University, Shanghai 200444, China.
Jingqi ChenInstitute of Nanochemistry and Nanobiology, Shanghai University, Shanghai 200444, China.
Rong JinInstitute of Nanochemistry and Nanobiology, Shanghai University, Shanghai 200444, China.
Xiaoyong DengInstitute of Nanochemistry and Nanobiology, Shanghai University, Shanghai 200444, China.
Haifang WangInstitute of Nanochemistry and Nanobiology, Shanghai University, Shanghai 200444, China; hwang@shu.edu.cn ancao@shu.edu.cn.
Zhonglian CaoSchool of Pharmacy, Fudan University, Shanghai 201203, China.
Yuanfang LiuInstitute of Nanochemistry and Nanobiology, Shanghai University, Shanghai 200444, China.
Aoneng CaoInstitute of Nanochemistry and Nanobiology, Shanghai University, Shanghai 200444, China; hwang@shu.edu.cn ancao@shu.edu.cn.ORCID 0000-0002-1168-3623

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To impart biomedical functions to nanoparticles (NPs), the common approach is to conjugate functional groups onto NPs by dint of the functions of those groups per se. It is still beyond current reach to create protein-like specific interactions and functions on NPs by conformational engineering of nonfunctional groups on NPs. Here, we develop a conformational engineering method to create an NP-based artificial antibody, denoted "Goldbody," through conformational reconstruction of the complementary-determining regions (CDRs) of natural antibodies on gold NPs (AuNPs). The seemingly insurmountable task of controlling the conformation of the CDR loops, which are flexible and nonfunctional in the free form, was accomplished unexpectedly in a simple way. Upon anchoring both terminals of the free CDR loops on AuNPs, we managed to reconstruct the "active" conformation of the CDR loops by tuning the span between the two terminals and, as a result, the original specificity was successfully reconstructed on the AuNPs. Two Goldbodies have been created by this strategy to specifically bind with hen egg white lysozyme and epidermal growth factor receptor, with apparent affinities several orders of magnitude stronger than that of the original natural antibodies. Our work demonstrates that it is possible to create protein-like functions on NPs in a protein-like way, namely by tuning flexible surface groups to the correct conformation. Given the apparent merits, including good stability, of Goldbodies, we anticipate that a category of Goldbodies could be created to target different antigens and thus used as substitutes for natural antibodies in various applications.

Indexed as

Antibodies, MonoclonalComplementarity Determining RegionsGoldMetal NanoparticlesProtein ConformationAntibodies, MonoclonalComplementarity Determining RegionsGoldartificial antibodyconformation engineeringEGFRGoldbodynanoparticle

Identifiers

PMID29255034
PMCPMC5776806

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.